CG-806 for Acute Myeloid Leukemia and High-Risk MDS
Recruiting at 9 trial locations
RB
NK
Overseen ByNawazish Khan, MD, MS
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: Aptose Biosciences Inc.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Trial Summary
What is the purpose of this trial?
This study is being done to evaluate the safety, tolerability and antitumor activity of oral CG-806 (luxeptinib) for the treatment of patients with Acute Myeloid Leukemia (except APML), secondary AML, therapy-related AML, or higher-risk MDS, whose disease has relapsed, is refractory or who are ineligible for or intolerant of intensive chemotherapy or transplantation.
Research Team
RB
Rafael Bejar, MD, PhD
Principal Investigator
Aptose Biosciences Inc.
Eligibility Criteria
This trial is for adults over 18 with relapsed or stubborn Acute Myeloid Leukemia (AML) or high-risk Myelodysplastic Syndrome (MDS), who can't have intense chemo or a transplant. They should be fairly active, able to swallow pills, and not on other experimental drugs recently.Inclusion Criteria
My blood counts are within normal ranges, unless caused by my condition.
You are expected to live for at least 3 more months.
My kidney, liver, and heart are functioning well.
See 3 more
Exclusion Criteria
I haven't received any cell-based immune therapy in the last 4 weeks.
I haven't taken experimental drugs or had chemotherapy in the last 14 days.
I have GVHD and need drugs to suppress my immune system.
See 2 more
Treatment Details
Interventions
- CG-806
Trial OverviewThe study tests CG-806 (luxeptinib), an oral medication, to see if it's safe and effective against certain types of AML/MDS that haven't responded well to other treatments or when patients can't handle stronger therapies.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Dose Escalation and ExpansionExperimental Treatment1 Intervention
Dose Escalation and Expansion; CG-806 will be given orally in ascending doses in patients with relapsed or refractory AML or higher-risk MDS (escalation cohort), until the maximum tolerated dose or candidate recommended Phase 2 dose is reached. Followed up by up to 50 patients enrolled in the expansion cohort at the recommended dose.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Aptose Biosciences Inc.
Lead Sponsor
Trials
8
Recruited
850+
Other People Viewed
By Subject
By Trial
Related Searches
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.